Ascendis Pharma AS (BSP:A1SN34)
R$ 48.84 0 (0%) Market Cap: 2.92 Bil Enterprise Value: 5.48 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 05:00PM GMT
Release Date Price: R$39.78
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm a large-cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference this morning with Ascendis Pharma. Presenting for the company is going to be their CEO, Jan Mikkelsen. But before I pass it over to him, we're going to let Tim Lee from IR come up and do the forward-looking statement.

Timothy J. Lee;S;Senior Director of IR;Jan Moller Mikkelsen
Ascendis Pharma A;Ascendis Pharma A

/-

Good morning. Before we begin, I'd like to remind you this presentation will contain forward-looking statements, and our actual results and events could differ materially from those in the forward-looking statements. For additional information concerning the factors that cause actual results to differ materially, please see our forward-looking statements section in the press release yesterday and our SEC filings for the associated risk factors. With that, Jan.

- /

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot